Total Funding
85
56
Total FundingSeries A raised
Growth Score
-4 pts
Heat Score
-5 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
19600
SyntheX is a biotechnology company reimagining precision therapeutics with new drug discovery technologies focused on protein modulation.
Maria Soloveychik: Chief Executive Officer & Co-Founder
Tri Luong: Head of Finance and Operations
About the Company
SyntheX expands the druggable proteome using synthetic biology-driven drug discovery platforms. The platforms rely on empirical intracellular selection to discover protein interaction modulators. These can discover compounds that disrupt a specific protein-protein interaction (PPI), or achieve the inverse, and bring an E3 ubiquitin ligase and a
neosubstrate of interest together to achieve functional protein degradation. In addition to external discovery collaborations, the platforms have generated an internal oncology pipeline focused on unique mechanisms of action around genetically validated targets.
Women Founded
Women Led
